Cartiva, Inc., an Alpharetta, Ga.-based developer of innovative products for the treatment of cartilage injuries and osteoarthritis, secured $8.5m in Series D financing.
The round was led by New Enterprise Associates (NEA) with participation from new investor Windham Ventures Partners.
The company intends to use the funds for the PMA approval of its Cartiva Synthetic Cartilage Implant, the support of post 510(k) clearance clinical evaluations of its ProxiFuse Hammertoe Correction System and its GRIP Study evaluating Cartiva SCI in the treatment of osteoarthritis at the base of the thumb.
Led by Tim Patrick, President and CEO, Cartiva develops and markets innovative solutions for patients with osteoarthritis, cartilage damage and other musculoskeletal conditions. It recently announced completion of the MOTION Study, a 236 patient, randomized, prospective study of a synthetic cartilage implant for the treatment of osteoarthritis of the great toe.
FinSMEs
11/05/2015